Bioinformatics Across the Cutaneous Scar Spectrum: Molecular States, Digital Phenotypes and Clinical Translation
5 affiliations
- 1Department of Plastic Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, People’s Republic of China
- 2Department of General Practice Residency Training Base, The First Affiliated Hospital of Naval Medical University, Shanghai, People’s Republic of China
- 3Department of Orthopedic Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, People’s Republic of China
- 4School of Exercise and Health, Shanghai University of Sport, Shanghai, People’s Republic of China
- 5Department of Burn and Plastic Surgery, Marine Corps Hospital, People’s Liberation Army Navy, Shanghai, People’s Republic of China
Abstract
Cutaneous scarring spans regenerative and normal remodelling; keloid, hypertrophic, atrophic and contractile outcomes; dyspigmentation; radiation- and inherited-fragility-associated fibrosis; and rare malignant transformation. Diagnostic labels alone do not capture the molecular, cellular, spatial and clinical states that shape these outcomes. This review is the first to treat the whole cutaneous scar spectrum, rather than keloid and hypertrophic scar alone, as a single computable phenotype space, and to audit jointly the provenance of the underlying datasets and the depth of validation of the resulting models. We searched four sources (PubMed, Europe PMC, OpenAlex and Crossref) on 20 June 2026 and combined systematic searching with evidence mapping; 26,575 records were identified, 920 entered the evidence map and 120 were prioritised for synthesis. Bulk studies identify tissue-level fibrotic programmes, whereas single-cell and spatial approaches resolve fibroblast, immune, endothelial and epithelial states and niches. Evidence remains concentrated in keloid and hypertrophic scar, and often reuses public datasets or extrapolates from associated cutaneous-fibrosis systems. Atrophic scars are represented mainly by quantitative imaging and treatment studies: topography and dermal loss are measurable, but no mature molecular or spatial atlas is available and atrophic acne scars are usually excluded from molecular cohorts. Scar pigmentation lacks interoperable labels, calibrated colour measurement, melanocyte-resolved spatial resources and skin-tone-stratified assessment. Fourteen studies applied artificial intelligence directly to scar data, but only one explicitly reported independent external validation. Molecular biomarkers and treatment-response models remain at discovery or internal-validation stages. Future work should standardise multidimensional phenotypes, build prospective skin-tone-stratified cohorts across the full scar spectrum, resolve rare populations such as melanocytes, and complete causal and external validation before clinical deployment.
Related
- LINC01537 Regulates Malignant Phenotypes and Predicts Prognosis in Breast Cancer, and Its Bioinformatics Analysis.
- Integrative bioinformatics analysis of Lianmei granules in diabetic nephropathy : Epidemiological and molecular insights
- The Diverse Clinical Spectrum of Noonan Syndrome in Pediatric Endocrinology: From Classical to Atypical Phenotypes
- Diverse Clinical Spectrum of TTN-Truncation Variant Cardiomyopathy: A Case Series Illustrating Asymptomatic, Arrhythmic, Recurrent Takotsubo, and Inflammatory Phenotypes.
- Cutaneous Neoplasms with Sebaceous Differentiation: A Comprehensive Update on Clinical, Histopathological and Molecular Classification.
BibTeX
@article{zhang2026bioinformatics,
title = {{Bioinformatics Across the Cutaneous Scar Spectrum: Molecular States, Digital Phenotypes and Clinical Translation}},
author = {Yuchen Zhang and Xuhui Wang and Jun Zhou and Jie Li and Wenjing Yang and Zishuo Wang and Yiyao Song and Zhiling Fan and Shuo Fang},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
month = oct,
doi = {10.2147/ccid.s648008},
url = {https://doi.org/10.2147/ccid.s648008},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Bioinformatics Across the Cutaneous Scar Spectrum: Molecular States, Digital Phenotypes and Clinical Translation
AU - Yuchen Zhang
AU - Xuhui Wang
AU - Jun Zhou
AU - Jie Li
AU - Wenjing Yang
AU - Zishuo Wang
AU - Yiyao Song
AU - Zhiling Fan
AU - Shuo Fang
PY - 2026
DA - 2026/10/26
JO - Clinical, Cosmetic and Investigational Dermatology
DO - 10.2147/ccid.s648008
UR - https://doi.org/10.2147/ccid.s648008
AB - Cutaneous scarring spans regenerative and normal remodelling; keloid, hypertrophic, atrophic and contractile outcomes; dyspigmentation; radiation- and inherited-fragility-associated fibrosis; and rare malignant transformation. Diagnostic labels alone do not capture the molecular, cellular, spatial and clinical states that shape these outcomes. This review is the first to treat the whole cutaneous scar spectrum, rather than keloid and hypertrophic scar alone, as a single computable phenotype space, and to audit jointly the provenance of the underlying datasets and the depth of validation of the resulting models. We searched four sources (PubMed, Europe PMC, OpenAlex and Crossref) on 20 June 2026 and combined systematic searching with evidence mapping; 26,575 records were identified, 920 entered the evidence map and 120 were prioritised for synthesis. Bulk studies identify tissue-level fibrotic programmes, whereas single-cell and spatial approaches resolve fibroblast, immune, endothelial and epithelial states and niches. Evidence remains concentrated in keloid and hypertrophic scar, and often reuses public datasets or extrapolates from associated cutaneous-fibrosis systems. Atrophic scars are represented mainly by quantitative imaging and treatment studies: topography and dermal loss are measurable, but no mature molecular or spatial atlas is available and atrophic acne scars are usually excluded from molecular cohorts. Scar pigmentation lacks interoperable labels, calibrated colour measurement, melanocyte-resolved spatial resources and skin-tone-stratified assessment. Fourteen studies applied artificial intelligence directly to scar data, but only one explicitly reported independent external validation. Molecular biomarkers and treatment-response models remain at discovery or internal-validation stages. Future work should standardise multidimensional phenotypes, build prospective skin-tone-stratified cohorts across the full scar spectrum, resolve rare populations such as melanocytes, and complete causal and external validation before clinical deployment.
SN - 1178-7015
ER -